Myeloproliferative neoplasm epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
|||
| (14 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myeloproliferative disease}} | {{Myeloproliferative disease}} | ||
{{CMG}}{{AE}} {{MJK}} | {{CMG}}{{AE}} {{MJK}} {{shyam}} | ||
==Overview== | ==Overview== | ||
The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide. | The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide. The different subtypes of myeloproliferative neoplasm have different incidence and prevalence statistics. Males are more commonly affected than females, and older persons are more commonly affected than younger persons. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide.<ref name="CDC">Centers for Disease Control and Prevention. WTC Health Program.Myeloid Malignancieshttp://www.cdc.gov/wtc/pdfs/WTCHP_PP_MyeloidMalignancies_02012014.pdf</ref> | *The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide.<ref name="CDC">Centers for Disease Control and Prevention. WTC Health Program.Myeloid Malignancieshttp://www.cdc.gov/wtc/pdfs/WTCHP_PP_MyeloidMalignancies_02012014.pdf</ref> This statistic includes all eight subtypes of myeloproliferative neoplasm. There are varying incidences for the different subtypes of myeloproliferative neoplasm. | ||
*The incidence of polycythemia vera is 0.4-2.8 per 100,000 persons per year.<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=4363847 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref> | |||
*The incidence of essential thrombocythemia is 0.38-1.7 per 100,000 persons per year.<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=4363847 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref> | |||
*The incidence of primary myelofibrosis is 0.1-1 per 100,000 persons per year.<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=4363847 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref> | |||
===Prevalence=== | |||
*The prevalence of myeloproliferative neoplasm depends on the particular subtype. | |||
*The prevalence of polycythemia vera is 44-57 per 100,000 persons.<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=4363847 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref> | |||
*The prevalence of essential thrombocythemia is 38-57 per 100,000 persons.<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=4363847 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref> | |||
*The prevalence of primary myelofibrosis is 4-6 per 100,000 persons.<ref name="pmid25810569">{{cite journal| author=Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J et al.| title=Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. | journal=Indian J Med Paediatr Oncol | year= 2015 | volume= 36 | issue= 1 | pages= 3-16 | pmid=25810569 | doi=10.4103/0971-5851.151770 | pmc=4363847 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25810569 }} </ref> | |||
===Age=== | ===Age=== | ||
The prevalence of myeloproliferative neoplasm increases with age. | *The prevalence of myeloproliferative neoplasm increases with age.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215 }} </ref> | ||
*The average age of diagnosis is 60-70.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215 }} </ref> | |||
===Gender=== | ===Gender=== | ||
Males are more commonly affected with myeloproliferative neoplasm than females. | *Males are more commonly affected with myeloproliferative neoplasm than females.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215 }} </ref> | ||
*Females are more likely to be affected by the abdominal symptoms of myeloproliferative neoplasm.<ref name="pmid27540137">{{cite journal| author=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S et al.| title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. | journal=Haematologica | year= 2017 | volume= 102 | issue= 1 | pages= 85-93 | pmid=27540137 | doi=10.3324/haematol.2016.149559 | pmc=5210236 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27540137 }} </ref> | |||
*Females are also more likely to develop thrombocytopenia than males.<ref name="pmid27540137">{{cite journal| author=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S et al.| title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. | journal=Haematologica | year= 2017 | volume= 102 | issue= 1 | pages= 85-93 | pmid=27540137 | doi=10.3324/haematol.2016.149559 | pmc=5210236 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27540137 }} </ref>. | |||
*Females have a shorter disease duration. | |||
===Race=== | |||
The prevalence of myeloproliferative neoplasm does not vary by race.<ref name="pmid18443215">{{cite journal| author=Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al.| title=Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. | journal=Blood | year= 2008 | volume= 112 | issue= 1 | pages= 45-52 | pmid=18443215 | doi=10.1182/blood-2008-01-134858 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18443215 }} </ref> | |||
==References== | ==References== | ||
| Line 19: | Line 38: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 05:50, 28 June 2018
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm epidemiology and demographics |
|
FDA on Myeloproliferative neoplasm epidemiology and demographics |
|
on Myeloproliferative neoplasm epidemiology and demographics |
|
Myeloproliferative neoplasm epidemiology and demographics in the news |
|
Blogs on Myeloproliferative neoplasm epidemiology and demographics |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide. The different subtypes of myeloproliferative neoplasm have different incidence and prevalence statistics. Males are more commonly affected than females, and older persons are more commonly affected than younger persons.
Epidemiology and Demographics
Incidence
- The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide.[1] This statistic includes all eight subtypes of myeloproliferative neoplasm. There are varying incidences for the different subtypes of myeloproliferative neoplasm.
- The incidence of polycythemia vera is 0.4-2.8 per 100,000 persons per year.[2]
- The incidence of essential thrombocythemia is 0.38-1.7 per 100,000 persons per year.[2]
- The incidence of primary myelofibrosis is 0.1-1 per 100,000 persons per year.[2]
Prevalence
- The prevalence of myeloproliferative neoplasm depends on the particular subtype.
- The prevalence of polycythemia vera is 44-57 per 100,000 persons.[2]
- The prevalence of essential thrombocythemia is 38-57 per 100,000 persons.[2]
- The prevalence of primary myelofibrosis is 4-6 per 100,000 persons.[2]
Age
- The prevalence of myeloproliferative neoplasm increases with age.[3]
- The average age of diagnosis is 60-70.[3]
Gender
- Males are more commonly affected with myeloproliferative neoplasm than females.[3]
- Females are more likely to be affected by the abdominal symptoms of myeloproliferative neoplasm.[4]
- Females are also more likely to develop thrombocytopenia than males.[4].
- Females have a shorter disease duration.
Race
The prevalence of myeloproliferative neoplasm does not vary by race.[3]
References
- ↑ Centers for Disease Control and Prevention. WTC Health Program.Myeloid Malignancieshttp://www.cdc.gov/wtc/pdfs/WTCHP_PP_MyeloidMalignancies_02012014.pdf
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Agarwal MB, Malhotra H, Chakrabarti P, Varma N, Mathews V, Bhattacharyya J; et al. (2015). "Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia". Indian J Med Paediatr Oncol. 36 (1): 3–16. doi:10.4103/0971-5851.151770. PMC 4363847. PMID 25810569.
- ↑ 3.0 3.1 3.2 3.3 Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA; et al. (2008). "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs". Blood. 112 (1): 45–52. doi:10.1182/blood-2008-01-134858. PMID 18443215.
- ↑ 4.0 4.1 Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S; et al. (2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.